Neogy A B, Vouldoukis I, da Costa J M, Monjour L
Laboratoire de Parasitologie, Faculté de Médecine Pitié-Salpétrière, Paris, France.
Vet Parasitol. 1994 Sep;54(4):367-73. doi: 10.1016/0304-4017(94)90003-5.
In an attempt to obtain therapeutic success against canine visceral leishmaniosis, the potential of LiF2 antigen (Leishmania infantum-derived Fraction 2, 94-67 kDa), given alone or in combination with the chemotherapeutic agent N-methylglucamine antimonate, was compared with conventional chemotherapy with that drug. Absence of any parasite in direct microscopic examination of bone-marrow aspirates in treated dogs was considered a parasitological cure, i.e. therapeutic success. Results showed that the disappearance of clinical symptoms did not always indicate parasitological healing in dogs. The parasitological healing rates with chemotherapy and immunotherapy alone were 37.5% and 25% respectively, in contrast to the 100% cure rate observed with chemotherapy combined with immunotherapy. The development of a protective response in dogs, as measured by the in vitro leishmanicidal activity of monocyte-derived macrophages in the presence of autologous lymphocytes, was found to correlate well with the success of therapy. The overall findings of this study give an important insight into the immunotherapeutic strategy by which therapeutic success can be achieved in canine visceral leishmaniosis.
为了在治疗犬内脏利什曼病方面取得成功，研究人员比较了单独使用LiF2抗原（源自婴儿利什曼原虫的第2组分，94 - 67 kDa）或与化疗药物葡甲胺锑酸盐联合使用时的治疗效果，并与仅使用该药物进行传统化疗的效果进行了对比。在对治疗后的犬骨髓穿刺物进行直接显微镜检查时，未发现任何寄生虫被视为寄生虫学治愈，即治疗成功。结果表明，犬的临床症状消失并不总是意味着寄生虫学治愈。单独使用化疗和免疫疗法的寄生虫学治愈率分别为37.5%和25%，而化疗与免疫疗法联合使用时的治愈率为100%。研究发现，通过在自体淋巴细胞存在的情况下，用单核细胞衍生的巨噬细胞的体外杀利什曼原虫活性来衡量，犬体内保护性反应的发展与治疗的成功密切相关。这项研究的总体结果为犬内脏利什曼病的免疫治疗策略提供了重要见解，通过该策略可实现治疗成功。
